J Korean Med Sci.  2023 Jun;38(23):e206. 10.3346/jkms.2023.38.e206.

Case 11: A 31-Year-Old Woman With Abdominal Pain

• Kim J
• Yang Y
• Jeong C
• Yang BR
• Kim MK
• Lee SH
• Song KH

• KMID: 2543884
• DOI: http://doi.org/10.3346/jkms.2023.38.e206

Figure

• 

  Fig. 1 Changing trend of strip blood sugar tests and treatment during hospitalization.ER = emergency room, U = units.

Reference

1. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015; 100(8):2849–2852. PMID: 26086329.

2. Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: a missed diagnosis. World J Diabetes. 2021; 12(5):514–523. PMID: 33995841.

3. Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D, et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care. 2016; 39(11):2036–2041. PMID: 27561923.

4. Monami M, Nreu B, Zannoni S, Lualdi C, Mannucci E. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials. Diabetes Res Clin Pract. 2017; 130:53–60. PMID: 28570924.

5. Douros A, Lix LM, Fralick M, Dell’Aniello S, Shah BR, Ronksley PE, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med. 2020; 173(6):417–425. PMID: 32716707.

6. Wolfsdorf JI, Ratner RE. SGLT inhibitors for type 1 diabetes: proceed with extreme caution. Diabetes Care. 2019; 42(6):991–993. PMID: 31110116.

7. Yang H, Choi E, Park E, Na E, Chung SY, Kim B, et al. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: a retrospective cohort study in Korea. Pharmacol Res Perspect. 2022; 10(1):e00910. PMID: 35005849.

8. Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019; 42(6):1147–1154. PMID: 30728224.

9. Goldenberg RM, Berard LD, Cheng AY, Gilbert JD, Verma S, Woo VC, et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016; 38(12):2654–2664.e1. PMID: 28003053.

10. Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter-2 inhibitors - lessons from a case series and strategies to decrease incidence. Endocr Pract. 2022; 28(9):884–888. PMID: 35753675.